Qual é o preço para Pell Bio-Med Technology Co., Ltd. (6949)

O preço para Pell Bio-Med Technology Co., Ltd. (6949) é $47.38

Qual é a capitalização de mercado para Pell Bio-Med Technology Co., Ltd. (6949)

A capitalização de mercado para Pell Bio-Med Technology Co., Ltd. (6949) é $3.11B

Receita de Pell Bio-Med Technology Co., Ltd. (6949)

Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.

Ano	Receita	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Receita

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Receita	Diferença de Receita	País
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Receita

Diferença de Receita

País